Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection

Jong Won Choi, Jun Yong Park, Sang Hoon Ahn, Ki Tae Yoon, Heung Kyu Ko, Do Yun Lee, Jong Tae Lee, Kyung Sik Kim, Jin Sub Choi, Kwang Hyub Han, Chae Yoon Chon, Do Young Kim

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objectives: To evaluate the efficacy and safety of transarterial chemoembolization (TACE) for recurrent hepatocellular carcinoma (HCC) after curative resection and to examine the factors associated with the prognosis in a single center. Methods: Between January 1995 and July 2006, 169 patients who had undergone curative resection were diagnosed with recurrent HCC. Of these, 114 patients underwent TACE as first-line therapy and were followed until July 2007. Results: At the time of resection, the mean tumor size was 4.8 ± 2.9 cm, and 96 (84.2%) patients had a single tumor. Single nodular recurrence was observed in 53 (46.5%) patients. The mean size of the recurrent HCC was 2.1 ±1.2 cm. The disease-free survival after TACE was 46.0%, 16.7%, and 13.4% at 1, 2, and 3 years, respectively. The overall survival after TACE was 77.8%, 53.6%, and 31.6% at 1, 3, and 5 years, respectively. Cox regression analysis revealed that the Edmonson grade and time to recurrence (>6 months) independently affected the disease-free survival (both P < 0.05). The time to recurrence (>6 months) and tumor-node-metastasis stage were associated with overall survival (both P < 0.05). Only 1 lethal complication (biliary sepsis) occurred after TACE. Conclusions: TACE seems to be a safe, effective treatment for recurrent HCC after curative resection.

Original languageEnglish
Pages (from-to)564-569
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume32
Issue number6
DOIs
Publication statusPublished - 2009 Dec 1

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection'. Together they form a unique fingerprint.

  • Cite this